U.S. And China Need “Safe Trade,” Not Just Free Trade
This article was originally published in PharmAsia News
Executive Summary
NEWARK, New Jersey - The U.S. and Chinese governments need to enforce international trade laws already in place to ensure product safety if pharmaceutical companies from both countries are to continue developing global supply chains, according to Michael Santoro, professor at Rutgers University Business School's Lerner Center for Pharmaceutical Management
You may also be interested in...
U.S. Congress Expands Probe Into Ranbaxy’s AIDS Drugs Supplied To Developing Nations
MUMBAI - Four leaders of the U.S. Congressional Committee on Energy and Commerce - John Dingell, Bart Stupak, Joe Barton and John Shimkus have expanded their investigations into U.S. FDA's handling of Ranbaxy's anti-AIDS drugs that are supplied to African and other developing nations as part of the President's Emergency Plan for AIDS Relief program
Import Safety Agreement Further Entwines FDA/China Regulatory Process
Chinese manufacturers of certain drugs or active pharmaceutical ingredients selected by FDA will have to meet new registration standards as part of a memorandum of understanding signed Dec. 11 in Beijing by HHS, FDA and China's State Food and Drug Administration
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).